MedTrace Logo

Ovarian Stimulation With FSH Alone Versus FSH Plus GnRH Antagonist in an Oocyte Donor/Recipient Programme

NCT05759871 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-03-10

No results posted yet for this study

Summary

The aim of this study is to compare the efficacy of a protocol using FSH alone with that of a protocol using FSH plus a GnRH antagonist for controlled ovarian hyperstimulation in cycles of elective freezing in the context of a donor/recipient programme.

Conditions

  • Premature Luteinisation
  • Progesterone Elevation

Interventions

OTHER

GnRH antagonist

The GnRH antagonist in the control group (standard therapy) is administered from day 6 of FSH treatment at the dose of 0.25 mg per day until the triggering day and is injected each time immediately after the injection of FSH.

Sponsors & Collaborators

  • Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece

    collaborator UNKNOWN

  • Embryoland, Athens, Greece

    collaborator UNKNOWN

  • Embryolab IVF Unit, Thessaloniki, Greece

    collaborator UNKNOWN

  • Assisting Nature IVF Unit, Thessaloniki, Greece

    collaborator UNKNOWN

  • HYGEIA IVF - Embryogenesis A.R.T. Unit, Athens, Greece

    collaborator UNKNOWN

  • Institute of Fertility, Athens, Greece

    collaborator UNKNOWN

  • Mitosis IVF Centre, Pireas, Greece

    collaborator UNKNOWN

  • National and Kapodistrian University of Athens

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
32 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2024-03-01
Completion
2024-07-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05759871 on ClinicalTrials.gov